A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Clinical trial NCT06284486 · RECRUITING

Trial details

NCT number: NCT06284486
Sponsor: M.D. Anderson Cancer Center
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia

Start date: 2024-09-23
Primary completion: 2026-12-30
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.